Skip to main content
Erschienen in: Inflammation Research 1/2012

01.01.2012 | Original Research Paper

C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia

verfasst von: Jaime Haidet, Vincenza Cifarelli, Massimo Trucco, Patrizia Luppi

Erschienen in: Inflammation Research | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

We investigated C-peptide effects on inflammatory cytokine release and adhesion of monocytes exposed to high glucose and lipopolysaccharide (LPS) in vitro.

Materials and methods

Monocytic cells (U-937) were cultured in the presence of 30 mmol/L glucose and stimulated with 0.5 ng/μL LPS in the presence or absence of C-peptide (1 μmol/L) for 24 h to induce inflammatory cytokine secretion. Adhesion of U-937 monocytes to human aortic endothelial cells (HAEC) was also studied in the presence or absence of C-peptide. Concentrations of IL-6, IL-8, macrophage inflammatory protein(MIP)-1α, and MIP-1β in supernatants from LPS-stimulated U-937 monocytes were assessed by Luminex. To gain insights into potential intracellular signaling pathways affected by C-peptide, we investigated nuclear translocation of nuclear factor(NF)-κB p65/p50 subunits by western blot in LPS-treated U-937 cells. The effect of C-peptide on LPS-induced phosphorylation of the cytoplasmic protein IκB-α was also investigated by immunoblotting.

Results

Addition of C-peptide significantly reduced cytokine secretion from LPS-stimulated U-937 monocytes. Adhesion of U-937 cells to HAEC was also significantly reduced by C-peptide. These effects were accompanied by reduced NF-κB p65/p50 nuclear translocation and decreased phosphorylation of IκB-α.

Conclusions

We conclude that, in conditions of hyperglycemia, C-peptide reduces monocytes activation via inhibition of the NF-κB pathway
Literatur
1.
Zurück zum Zitat Libby P, Nathan DM, Abraham K, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases working group on cardiovascular complications of type 1 diabetes mellitus. Circulation. 2005;111(25):3489–93.PubMedCrossRef Libby P, Nathan DM, Abraham K, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases working group on cardiovascular complications of type 1 diabetes mellitus. Circulation. 2005;111(25):3489–93.PubMedCrossRef
2.
Zurück zum Zitat Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328(23):1676–85.PubMedCrossRef Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328(23):1676–85.PubMedCrossRef
3.
Zurück zum Zitat Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab. 2010;5(1):19–28.PubMed Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab. 2010;5(1):19–28.PubMed
4.
Zurück zum Zitat Devaraj S, Glaser N, Griffen S, et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55(3):774–9.PubMedCrossRef Devaraj S, Glaser N, Griffen S, et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55(3):774–9.PubMedCrossRef
5.
Zurück zum Zitat Plesner A, Greenbaum CJ, Gaur LK, et al. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol. 2002;56(5):522–9.PubMedCrossRef Plesner A, Greenbaum CJ, Gaur LK, et al. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol. 2002;56(5):522–9.PubMedCrossRef
6.
Zurück zum Zitat Erbagci AB, Tarakcioglu M, Coskun Y, et al. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem. 2001;34(8):645–50.PubMedCrossRef Erbagci AB, Tarakcioglu M, Coskun Y, et al. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem. 2001;34(8):645–50.PubMedCrossRef
7.
Zurück zum Zitat Rosa JS, Flores RL, Oliver SR, et al. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes. 2008;9(1):9–16.PubMedCrossRef Rosa JS, Flores RL, Oliver SR, et al. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes. 2008;9(1):9–16.PubMedCrossRef
8.
Zurück zum Zitat Cifarelli V, Libman IM, Deluca A, et al. Increased expression of monocyte CD11b (Mac-1) in overweight recent-onset type 1 diabetic children. Rev Diabet Stud. 2007;4(2):112–7.PubMedCrossRef Cifarelli V, Libman IM, Deluca A, et al. Increased expression of monocyte CD11b (Mac-1) in overweight recent-onset type 1 diabetic children. Rev Diabet Stud. 2007;4(2):112–7.PubMedCrossRef
9.
Zurück zum Zitat Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56(11):2790–6.PubMedCrossRef Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56(11):2790–6.PubMedCrossRef
10.
Zurück zum Zitat Saraheimo M, Teppo AM, Forsblom C, et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 2003;46(10):1402–7.PubMedCrossRef Saraheimo M, Teppo AM, Forsblom C, et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 2003;46(10):1402–7.PubMedCrossRef
11.
Zurück zum Zitat Schalkwijk CG, Ter Wee PM, Stehouwer CD. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction. Ann NY Acad Sci. 2005;1043:662–70.PubMedCrossRef Schalkwijk CG, Ter Wee PM, Stehouwer CD. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction. Ann NY Acad Sci. 2005;1043:662–70.PubMedCrossRef
12.
Zurück zum Zitat Zuckerbraun BS, McCloskey CA, Mahidhara RS, et al. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J Vasc Surg. 2003;38(4):812–9.PubMedCrossRef Zuckerbraun BS, McCloskey CA, Mahidhara RS, et al. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J Vasc Surg. 2003;38(4):812–9.PubMedCrossRef
13.
Zurück zum Zitat Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997;3(8):894–9.PubMedCrossRef Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997;3(8):894–9.PubMedCrossRef
14.
Zurück zum Zitat Vish MG, Mangeshkar P, Piraino G, et al. Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med. 2007;35(5):1348–55.PubMedCrossRef Vish MG, Mangeshkar P, Piraino G, et al. Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med. 2007;35(5):1348–55.PubMedCrossRef
15.
Zurück zum Zitat Scalia R, Coyle KM, Levine BJ, et al. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J. 2000;14(14):2357–64.PubMedCrossRef Scalia R, Coyle KM, Levine BJ, et al. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J. 2000;14(14):2357–64.PubMedCrossRef
16.
Zurück zum Zitat Young LH, Ikeda Y, Scalia R, et al. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2000;279(4):H1453–9.PubMed Young LH, Ikeda Y, Scalia R, et al. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2000;279(4):H1453–9.PubMed
17.
Zurück zum Zitat Luppi P, Cifarelli V, Tse H, et al. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia. 2008;51(8):1534–43.PubMedCrossRef Luppi P, Cifarelli V, Tse H, et al. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia. 2008;51(8):1534–43.PubMedCrossRef
18.
Zurück zum Zitat Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71–6.PubMedCrossRef Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30(1):71–6.PubMedCrossRef
19.
Zurück zum Zitat Johansson BL, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med. 2000;17(3):181–9.PubMedCrossRef Johansson BL, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med. 2000;17(3):181–9.PubMedCrossRef
20.
Zurück zum Zitat Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes. 2005;54(5):1497–505.PubMedCrossRef Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes. 2005;54(5):1497–505.PubMedCrossRef
21.
Zurück zum Zitat Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32(2):301–5.PubMedCrossRef Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32(2):301–5.PubMedCrossRef
22.
Zurück zum Zitat Thompson DM, Begg IS, Harris C, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation. 2008;85(10):1400–5.PubMedCrossRef Thompson DM, Begg IS, Harris C, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation. 2008;85(10):1400–5.PubMedCrossRef
23.
Zurück zum Zitat Remuzzi A, Cornolti R, Bianchi R, et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia. 2009;52(12):2653–61.PubMedCrossRef Remuzzi A, Cornolti R, Bianchi R, et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia. 2009;52(12):2653–61.PubMedCrossRef
24.
Zurück zum Zitat Gremizzi C, Vergani A, Paloschi V, et al. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15(1):119–23.PubMedCrossRef Gremizzi C, Vergani A, Paloschi V, et al. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15(1):119–23.PubMedCrossRef
25.
Zurück zum Zitat Robertson RP. Update on transplanting beta cells for reversing type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):655–67.PubMedCrossRef Robertson RP. Update on transplanting beta cells for reversing type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):655–67.PubMedCrossRef
26.
Zurück zum Zitat Luppi P, Geng X, Cifarelli V, et al. C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia. 2009;52(10):2218–28.PubMedCrossRef Luppi P, Geng X, Cifarelli V, et al. C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia. 2009;52(10):2218–28.PubMedCrossRef
27.
Zurück zum Zitat Piga R, Naito Y, Kokura S, et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis. 2007;193(2):328–34.PubMedCrossRef Piga R, Naito Y, Kokura S, et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis. 2007;193(2):328–34.PubMedCrossRef
28.
Zurück zum Zitat Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med. 2004;36(2):233–47.PubMedCrossRef Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med. 2004;36(2):233–47.PubMedCrossRef
29.
Zurück zum Zitat Schram MT, Chaturvedi N, Schalkwijk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003;26(7):2165–73.PubMedCrossRef Schram MT, Chaturvedi N, Schalkwijk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003;26(7):2165–73.PubMedCrossRef
30.
Zurück zum Zitat Beyan H, Goodier MR, Nawroly NS, et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes. 2006;55(12):3439–45.PubMedCrossRef Beyan H, Goodier MR, Nawroly NS, et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes. 2006;55(12):3439–45.PubMedCrossRef
31.
Zurück zum Zitat Litherland SA, Xie XT, Hutson AD, et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest. 1999;104(4):515–23.PubMedCrossRef Litherland SA, Xie XT, Hutson AD, et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest. 1999;104(4):515–23.PubMedCrossRef
32.
Zurück zum Zitat Cifarelli V, Luppi P, Tse HM, et al. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis. 2008;201(2):248–57.PubMedCrossRef Cifarelli V, Luppi P, Tse HM, et al. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis. 2008;201(2):248–57.PubMedCrossRef
33.
Zurück zum Zitat Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242(4878):540–6.PubMedCrossRef Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242(4878):540–6.PubMedCrossRef
34.
Zurück zum Zitat Brand K, Page S, Walli AK, et al. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997;82(2):297–304.PubMed Brand K, Page S, Walli AK, et al. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol. 1997;82(2):297–304.PubMed
35.
Zurück zum Zitat Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys. 2002;397:342–4.PubMedCrossRef Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys. 2002;397:342–4.PubMedCrossRef
36.
Zurück zum Zitat Cifarelli V, Geng X, Styche A, Lakomy B, Trucco M, Luppi P. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia. 2011. doi:10.1007/s00125-011-2251-0. Cifarelli V, Geng X, Styche A, Lakomy B, Trucco M, Luppi P. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia. 2011. doi:10.​1007/​s00125-011-2251-0.
37.
Zurück zum Zitat Dandona P, Chaudhuri A, Ghanim H, et al. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin Thorac Cardiovasc Surg. 2006;18(4):293–301.PubMedCrossRef Dandona P, Chaudhuri A, Ghanim H, et al. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin Thorac Cardiovasc Surg. 2006;18(4):293–301.PubMedCrossRef
38.
Zurück zum Zitat Hyun E, Ramachandran R, Cenac N, et al. Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response. J Immunol. 2010;184(5):2702–9.PubMedCrossRef Hyun E, Ramachandran R, Cenac N, et al. Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response. J Immunol. 2010;184(5):2702–9.PubMedCrossRef
39.
Zurück zum Zitat Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3):1082–8.PubMedCrossRef Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3):1082–8.PubMedCrossRef
40.
Zurück zum Zitat Li H, Xu L, Dunbar JC, et al. Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. Urology. 2004;64(3):622–7.PubMedCrossRef Li H, Xu L, Dunbar JC, et al. Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. Urology. 2004;64(3):622–7.PubMedCrossRef
41.
Zurück zum Zitat Mughal RS, Scragg JL, Lister P, et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia. 2010;53(8):1761–71.PubMedCrossRef Mughal RS, Scragg JL, Lister P, et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia. 2010;53(8):1761–71.PubMedCrossRef
42.
Zurück zum Zitat Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev. 2003;19(5):375–85.PubMedCrossRef Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev. 2003;19(5):375–85.PubMedCrossRef
43.
Zurück zum Zitat Al-Rasheed NM, Chana RS, Baines RJ, et al. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem. 2004;279(48):49747–54.PubMedCrossRef Al-Rasheed NM, Chana RS, Baines RJ, et al. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem. 2004;279(48):49747–54.PubMedCrossRef
Metadaten
Titel
C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia
verfasst von
Jaime Haidet
Vincenza Cifarelli
Massimo Trucco
Patrizia Luppi
Publikationsdatum
01.01.2012
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 1/2012
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0384-8

Weitere Artikel der Ausgabe 1/2012

Inflammation Research 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.